Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026
Wolfgang Miesbach and Sebastien Lacroix-Desmazes
Mar 8, 2026, 15:49

Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“A standout session at GTH was ‘The immunogenicity of therapeutic proteins in hemostasis – an overview’ by Sebastien Lacroix-Desmazes.

The talk clearly highlighted the immunological challenges in haemophilia — from classical FVIII inhibitors to gene therapy and anti-drug antibodies (ADAs) against newer engineered therapies.

One especially interesting point: FVIII-mimetic bispecific antibodies do not seem to share the same immunogenic profile

  • Emicizumab։ ADA signal reported
  • NXT007։ ADA signal also observed in early studies
  • Mim8։ no ADA signal in the study presented

A likely reason is molecular design:

  • Emicizumab is a humanized and highly engineered bispecific antibody; such optimization can improve function, but may also introduce non-self sequences or neoepitopes.
  • NXT007, as a further optimized derivative, may retain or add immunogenic determinants.
  • Mim8, with a more fully human design strategy, may reduce immune recognition

Take-home message:

Shared mechanism does not equal shared immunogenicity. Even when therapies target the same pathway, immune responses can differ because of humanization strategy, sequence design, and epitope architecture.”

Wolfgang Miesbach

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.

anti-drug antibodies (ADAs) Emicizumab FVIII inhibitors Gene therapy GTH Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Sebastien Lacroix-Desmazes Wolfgang Miesbach
NewsFeed